Lyra Therapeutics, Inc. (LYRA)
| Market Cap | 496.97K -95.4% |
| Revenue (ttm) | 398.00K -74.1% |
| Net Income | -28.92M |
| EPS | -18.62 |
| Shares Out | 1.77M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 11,261 |
| Open | 0.4000 |
| Previous Close | 0.3400 |
| Day's Range | 0.2700 - 0.4000 |
| 52-Week Range | 0.0004 - 8.7480 |
| Beta | 0.71 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 14, 2026 |
About Lyra Therapeutics
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company’s product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the treatment of chronic rhinosinusitis (CRS); and LYR-220 for CRS patients wh... [Read more]
Financial Performance
In 2025, Lyra Therapeutics's revenue was $398,000, a decrease of -74.05% compared to the previous year's $1.53 million. Losses were -$28.92 million, -69.05% less than in 2024.
Financial StatementsNews
Lyra Therapeutics announces intention to file Form 25 for delisting from Nasdaq
Lyra Therapeutics (LYRA) announced its intention to voluntarily file a Form 25 Notification of Delisting with the U.S. Securities and Exchange Commission on Monday, April 20, 2026, to remove its…
Lyra Therapeutics, Inc. Announces Intention to Voluntarily File Form 25 for Delisting from Nasdaq and Subsequent Deregistration with the SEC
WATERTOWN, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (the "Company") today announced its intention to voluntarily file a Form 25 Notification of Delisting with the U.S. Securit...
Lyra Therapeutics Annual report: Q4 2025
Lyra Therapeutics has published its Q4 2025 annual report on March 31, 2026.
Lyra Therapeutics common stock to be delisted by Nasdaq
On February 2, Lyra Therapeutics (LYRA) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market notifying the company that Nasdaq has determined to delist the company’s...
Why Is Lyra Therapeutics Stock (LYRA) Down Today?
Lyra Therapeutics stock was down on Monday after the company revealed a pause to its operations.
Lyra Therapeutics suspends further development of LYR-210
Lyra Therapeutics (LYRA), announced that its Board of Directors has decided to suspend further development of LYR-210, the Company’s lead product candidate for the treatment of chronic rhinosinusitis....
Lyra Therapeutics Provides Corporate Update
WATERTOWN, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”) today announced that its Board of Directors has decided to suspend further developm...
Lyra Therapeutics reports Q3 EPS ($3.38), consensus ($4.07)
Reports Q3 revenue $25,000, consensus $154,250. “We are now focused on putting all the components in place for a new, confirmatory Phase 3 clinical trial to make progress toward a…
Lyra Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
– Company plans new, confirmatory Phase 3 clinical trial of LYR-210 for treatment of chronic rhinosinusitis (CRS) without nasal polyps, on path to NDA submission –
Lyra Therapeutics Earnings release: Q3 2025
Lyra Therapeutics released its Q3 2025 earnings on November 12, 2025, summarizing the period's financial results.
Lyra Therapeutics Quarterly report: Q3 2025
Lyra Therapeutics has published its Q3 2025 quarterly earnings report on November 12, 2025.
Lyra Therapeutics announces clinical plan for LYR-210
Lyra Therapeutics (LYRA) announced the Company’s clinical plan and upcoming oral presentation of results from the positive Phase 3 ENLIGHTEN 2 trial for LYR-210, the company’s lead product candidate f...
Lyra Therapeutics Announces Clinical Plan for LYR-210 and Late-Breaking Oral Presentation of Phase 3 ENLIGHTEN 2 Study
Company outlines clinical plan for LYR-210 based on FDA meeting on the path to NDA submission Positive ENLIGHTEN 2 results highlighted at the AAO-HNS 2025 Annual Meeting WATERTOWN, Mass., Oct. 06, 20...
Lyra Therapeutics reports Q2 EPS ($5.51), consensus ($4.78)
Reports Q2 revenue $183,000, consensus $181,250. “The positive results from our ENLIGHTEN 2 trial have enabled us to secure financing and are providing momentum to optimize our regulatory strategy and...
Lyra Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
– Positive ENLIGHTEN 2 Phase 3 results announced in June 2025 propel business activities in manufacturing, regulatory strategy and ENLIGHTEN clinical dataset analysis to advance path forward for LYR-2...
Lyra Therapeutics Quarterly report: Q2 2025
Lyra Therapeutics has published its Q2 2025 quarterly earnings report on August 12, 2025.
Lyra Therapeutics Earnings release: Q2 2025
Lyra Therapeutics released its Q2 2025 earnings on August 12, 2025, summarizing the period's financial results.
Lyra Therapeutics files to sell 846,744 shares of common stock for holders
17:16 EDT Lyra Therapeutics (LYRA) files to sell 846,744 shares of common stock for holders
Lyra Therapeutics Registration statement: Registration Filing
Lyra Therapeutics filed a registration statement on July 22, 2025, providing details about a securities offering with the SEC.
Lyra Therapeutics Announces Up to Approximately $15 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
Upfront Gross Proceeds of $5.0 Million, with Up to Approximately $9.8 Million of Additional Gross Proceeds Assuming the Cash Exercise in Full of Private Placement Warrants Upfront Gross Proceeds of $5...
Lyra Therapeutics target adjusted to $16 from $2 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Lyra Therapeutics (LYRA) to $16 from $2 and keeps a Neutral rating on the shares following the company’s reverse stock split. Published…
Lyra Therapeutics Slides: Corporate Presentation
Lyra Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 9, 2025.
Lyra Therapeutics Stock (LYRA) Rockets 530% on Phase 3 Trial Results
Lyra Therapeutics stock took off on Monday as investors reacted to positive Phase 3 clinical trial results.
Lyra Therapeutics Transcript: Study Result
Enlightened II phase III trial of LYR-210 in CRS met primary and key secondary endpoints, showing significant symptom and quality-of-life improvements with a strong safety profile. Plans are underway for FDA engagement and further studies in polyp patients.
Lyra Therapeutics Press release: Study Result
Lyra Therapeutics issued a press release on June 2, 2025, disclosing material business information to investors.